Waltham, MA, United States
Waltham, MA, United States

Time filter

Source Type

This report studies Cardiac Biomarker in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Alere  Roche Diagnostics  BG Medicine  Biomerieux  Critical Diagnostics  DiaDexus  Response Biomedical  Siemens Healthcare  Singulex  Thermo Scientific By types, the market can be split into  Creatine kinase (CK) MB  Troponin (cTnI and cTnT)  BNP & NT-proBNP  Myogloblin  Others (hs-CRP, D-Dimer, etc.) By Application, the market can be split into  Myocardial Infarction  Congestive Heart Failure  Acute Coronary Syndrome  Atherosclerosis  Others By Regions, this report covers (we can add the regions/countries as you want)  North America  China  Europe  Southeast Asia  Japan  India 1 Industry Overview of Cardiac Biomarker  1.1 Definition and Specifications of Cardiac Biomarker  1.1.1 Definition of Cardiac Biomarker  1.1.2 Specifications of Cardiac Biomarker  1.2 Classification of Cardiac Biomarker  1.2.1 Creatine kinase (CK) MB  1.2.2 Troponin (cTnI and cTnT)  1.2.3 BNP & NT-proBNP  1.2.4 Myogloblin  1.2.5 Others (hs-CRP, D-Dimer, etc.)  1.3 Applications of Cardiac Biomarker  1.3.1 Myocardial Infarction  1.3.2 Congestive Heart Failure  1.3.3 Acute Coronary Syndrome  1.3.4 Atherosclerosis  1.3.5 Others  1.4 Market Segment by Regions  1.4.1 North America  1.4.2 China  1.4.3 Europe  1.4.4 Southeast Asia  1.4.5 Japan  1.4.6 India 2 Manufacturing Cost Structure Analysis of Cardiac Biomarker  2.1 Raw Material and Suppliers  2.2 Manufacturing Cost Structure Analysis of Cardiac Biomarker  2.3 Manufacturing Process Analysis of Cardiac Biomarker  2.4 Industry Chain Structure of Cardiac Biomarker 3 Technical Data and Manufacturing Plants Analysis of Cardiac Biomarker  3.1 Capacity and Commercial Production Date of Global Cardiac Biomarker Major Manufacturers in 2015  3.2 Manufacturing Plants Distribution of Global Cardiac Biomarker Major Manufacturers in 2015  3.3 R&D Status and Technology Source of Global Cardiac Biomarker Major Manufacturers in 2015  3.4 Raw Materials Sources Analysis of Global Cardiac Biomarker Major Manufacturers in 2015 4 Global Cardiac Biomarker Overall Market Overview  4.1 2011-2016E Overall Market Analysis  4.2 Capacity Analysis  4.2.1 2011-2016E Global Cardiac Biomarker Capacity and Growth Rate Analysis  4.2.2 2015 Cardiac Biomarker Capacity Analysis (Company Segment)  4.3 Sales Analysis  4.3.1 2011-2016E Global Cardiac Biomarker Sales and Growth Rate Analysis  4.3.2 2015 Cardiac Biomarker Sales Analysis (Company Segment)  4.4 Sales Price Analysis  4.4.1 2011-2016E Global Cardiac Biomarker Sales Price  4.4.2 2015 Cardiac Biomarker Sales Price Analysis (Company Segment) 8 Major Manufacturers Analysis of Cardiac Biomarker  8.1 Alere  8.1.1 Company Profile  8.1.2 Product Picture and Specifications  8.1.2.1 Type I  8.1.2.2 Type II  8.1.2.3 Type III  8.1.3 Alere 2015 Cardiac Biomarker Sales, Ex-factory Price, Revenue, Gross Margin Analysis  8.1.4 Alere 2015 Cardiac Biomarker Business Region Distribution Analysis  8.2 Roche Diagnostics  8.2.1 Company Profile  8.2.2 Product Picture and Specifications  8.2.2.1 Type I  8.2.2.2 Type II  8.2.2.3 Type III  8.2.3 Roche Diagnostics 2015 Cardiac Biomarker Sales, Ex-factory Price, Revenue, Gross Margin Analysis  8.2.4 Roche Diagnostics 2015 Cardiac Biomarker Business Region Distribution Analysis  8.3 BG Medicine  8.3.1 Company Profile  8.3.2 Product Picture and Specifications  8.3.2.1 Type I  8.3.2.2 Type II  8.3.2.3 Type III  8.3.3 BG Medicine 2015 Cardiac Biomarker Sales, Ex-factory Price, Revenue, Gross Margin Analysis  8.3.4 BG Medicine 2015 Cardiac Biomarker Business Region Distribution Analysis  8.4 Biomerieux  8.4.1 Company Profile  8.4.2 Product Picture and Specifications  8.4.2.1 Type I  8.4.2.2 Type II  8.4.2.3 Type III


A quantitative proteomics workflow was implemented that provides extended plasma protein coverage by extensive protein depletion in combination with the sensitivity and breadth of analysis of twodimensional LC-MS/MS shotgun analysis. Abundant proteins were depleted by a two-stage process using IgY and Supermix depletion columns in series. Samples are then extensively fractionated by two-dimensional chromatography with fractions directly deposited onto MALDI plates. Decoupling sample fractionation from mass spectrometry facilitates a targeted MS/MS precursor selection strategy that maximizes measurement of a consistent set of peptides across experiments. Multiplexed stable isotope labeling provides quantification relative to a common reference sample and ensures an identical set of peptides measured in the set of samples (set of eight) combined in a single experiment. The more extensive protein depletion provided by the addition of the Supermix column did not compromise overall reproducibility of the measurements or the ability to reliably detect changes in protein levels between samples. The implementation of this workflow is presented for a case study aimed at generating molecular signatures for prediction of first heart attack. © 2011 American Chemical Society.


The present invention relates to materials and methods for predicting the risk of heart failure in a subject with Acute Coronary Syndrome. The invention further relates to monitoring the efficacy of treatment for heart failure in a subject with Acute Coronary Syndrome.


Patent
BG Medicine | Date: 2011-03-09

Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.


Patent
BG Medicine | Date: 2013-03-13

Biomarkers and methods are disclosed for diagnosing the risk of a myocardial infarction in an individual by measuring the levels of a set of biomarkers in a sample from an individual. A risk score is calculated for the individual by weighting the measured levels of the biomarkers. The risk score then is used to identify whether the individual is likely to experience a myocardial infarction. In addition, kits are disclosed that include a set of reagents for specifically measuring biomarker levels in a sample from an individual.


Patent
BG Medicine | Date: 2011-07-01

Described herein are materials and methods for predicting and monitoring a heart failure patients physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.


Patent
BG Medicine | Date: 2010-11-15

Biomarkers and methods are disclosed for diagnosing the risk of a myocardial infarction in an individual by measuring the levels of a set of biomarkers in a sample from an individual. A risk score is calculated for the individual by weighting the measured levels of the biomarkers. The risk score then is used to identify whether the individual is likely to experience a myocardial infarction. In addition, kits are disclosed that include a set of reagents for specifically measuring biomarker levels in a sample from an individual.


Described herein are materials and methods for predicting and/or monitoring preeclampsia and related conditions, including eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, left ventricular dysfunction, and heart failure, in a pregnant or post-partum woman. More specifically, use of the endogenous protein galectin-3 in predicting and/or monitoring preeclampsia and related conditions in a pregnant or post-partum woman is described. Also described are methods of preventing and/or treating preeclampsia and related conditions by inhibiting galectin-3.


Patent
BG Medicine | Date: 2010-08-25

The present invention relates to materials and methods for monitoring and predicting a heart failure patients physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.


Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.

Loading BG Medicine collaborators
Loading BG Medicine collaborators